According to the terms of the agreement, GeoPharma will manufacture and package Mucotrol and Cura will promote, distribute and sell Mucotrol with the two companies sharing in the net profits.
“We are excited by the potential of this agreement. Cura’s management has extensive experience in the oncology market and has achieved significant market share in the products it has introduced,” commented Mihir Taneja, GeoPharma’s CEO. “Cura plans to leverage its expertise to market Mucotrol to hospitals with major oncology centers across the country as well as larger private oncology practices and other secondary markets.”
The National Cancer Institute estimates that approximately 300,000 cancer patients in the US suffer from mucositis associated with cancer treatments.